Nashville Neonatal Group Joins MEDNAX Network
Mid-Tennessee Neonatology's 10 physicians and 14 neonatal nurse practitioners will practice as part of MEDNAX's Pediatrix Medical Group operating division, a national group practice of neonatal, maternal fetal, pediatric cardiology and other pediatric subspecialists.
Mid-Tennessee Neonatology Associates staffs seven NICUs, including the Level III Women's Hospital at Centennial and Middle Tennessee Medical Center. In addition, the practice provides hearings screen at a total eight hospitals, including six of the hospitals at which it provides neonatal and well-baby care. Combined patient volume for the practice is in excess of 22,000 annual NICU patient days.
"In Pediatrix we've found a partner that will help us to manage the growth that we anticipate for our practice, and that will allow us to participate in comprehensive clinical quality programs," said M. Sami Ismail, M.D., who founded the practice in 1989 and will continue as Pediatrix's Medical Director. "With Pediatrix's electronic physician note system we'll be able to better compare the quality of our group's patient care with neonatal practices across the country. We'll have the kind of evidence-based tools that will help us to improve care for our babies."
Mid-Tennessee Neonatology is a part of the statewide Tennessee Initiative for Perinatal Quality Care (TIPQC), a collaborative effort of neonatal and maternal-fetal medicine practices that is led by Vanderbilt University and is identifying opportunities to improve birth outcomes and deliver evidence-based medicine.
Neonatal and maternal-fetal medicine physicians practicing as part of Pediatrix in Memphis, Nashville, Chattanooga and Knoxville are participating in the collaborative, which will be using the Pediatrix QuIPS System (Quality Improvement Project System) to track neonatal and maternal-fetal outcomes for selected projects.
Mid-Tennessee Neonatology was acquired for cash, and the transaction is expected to be immediately accretive to MEDNAX's earnings. No additional terms of the transaction were disclosed.
MEDNAX, Inc., is a national medical group that comprises the nation's leading provider of neonatal, maternal-fetal and pediatric physician subspecialty services as well as anesthesia services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a unit of MEDNAX, was founded in 1979 and now includes neonatal physicians who provide services at more than 250 neonatal intensive care units, who collaborate with affiliated maternal-fetal medicine, pediatric cardiology and pediatric intensivist physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation's largest provider of newborn hearing screens. In 2007, the Company expanded into anesthesia services. Today, American Anesthesiology includes more than 450 anesthesiologists and advanced practitioners. MEDNAX, through its affiliated professional corporations, employs more than 1,275 physicians in 32 states and Puerto Rico. Additional information is available at www.mednax.com.
Certain statements and information in this press release may be deemed to contain forward-looking statements which may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made by MEDNAX's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled "Risk Factors", as well MEDNAX's current reports on Form 8-K, filed with the Securities and Exchange Commission.
SOURCE: MEDNAX, Inc.
Bob Kneeley, 954-384-0175, ext. 5300
Director, Investor Relations